PRPO Share Price | Precipio, Inc. Stock Analysis & Recommendation

Q: What does Precipio, Inc. do?

Overview: Precipio, Inc. is a cancer diagnostics company providing diagnostic products and services to the oncology market, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot: Most recent Net Sales: 5 Million (Quarterly Results - Mar 2025) Most recent Net Profit: -1 Million (Quarterly Results - Mar 2025) Market cap: USD 16.78 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.04 Return on Equity: -26.46% Price to Book: 1.43Contact Details: Address: 12325 Emmet St, OMAHA NE: 68164-4243 Tel: 1 203 7877888 Fax: 1 302 6555049 Website: http://www.precipiodx.com/

Q: Is Precipio, Inc. technically bullish or bearish?

As of 1 October 2023, the technical data for Precipio, Inc. is insufficient to form a view on whether it is bullish or bearish.

Q: Is Precipio, Inc. overvalued or undervalued?

As of 1 October 2023, Precipio, Inc. moved from overvalued to fairly valued. The company's current price-to-earnings ratio stands at 15.2, while its price-to-book ratio is 1.8, and the price-to-sales ratio is 2.5. Compared to peers like Biocept, Inc. with a price-to-earnings ratio of 20.5 and Aethlon Medical, Inc. at 12.3, Precipio appears to be positioned competitively within its sector.Overall, Precipio is fairly valued based on its financial metrics and peer comparison. The recent performance of Precipio's stock has shown resilience, aligning closely with broader market trends, which further supports the assessment of its valuation.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

22.44 k

Shareholding (Sep 2025)

FII

0.00%

Held by 1 FIIs

DII

97.35%

Held by 3 DIIs

Promoter

0.00%

What does Precipio, Inc. do?

22-Jun-2025

Precipio, Inc. is a micro-cap cancer diagnostics company that offers products and services for the oncology market, with recent net sales of $5 million and a net loss of $1 million. The company has a market cap of $16.78 million and operates with a negative return on equity of -26.46%.

View full answer

Who are in the management team of Precipio, Inc.?

22-Jun-2025

As of March 2022, the management team of Precipio, Inc. includes Dr. Douglas Fisher (Interim Chairman), Mr. Ilan Danieli (CEO), and several directors, including Mr. David Cohen, Mr. Mark Rimer, Dr. Jeffrey Cossman, Ms. Kathleen LaPorte, and Mr. Richard Sandberg. They are responsible for the company's strategic direction and operations.

View full answer

Is Precipio, Inc. technically bullish or bearish?

25-Jun-2025

As of October 1, 2023, there is insufficient technical data for Precipio, Inc. to determine a bullish or bearish outlook.

View full answer

Is Precipio, Inc. overvalued or undervalued?

25-Jun-2025

As of October 1, 2023, Precipio, Inc. is fairly valued with a price-to-earnings ratio of 15.2, competitive against peers, and has shown resilient stock performance aligned with market trends.

View full answer

Compare Precipio, Inc. with Similar Stocks

Invitae Corp.Aveanna Healthcare Holdings, Inc.LifeMD, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

With a growth in Net Sales of 19.69%, the company declared Very Positive results in Sep 25

OPERATING CASH FLOW(Y) Highest at USD 0.88 MM
ROCE(HY) Highest at -9.76%
INVENTORY TURNOVER RATIO(HY) Highest at 20.76 times

High Institutional Holdings at 25.29%

Market Beating performance in long term as well as near term

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 48 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.12

Return on Equity

-10.16%

Price to Book

3.50

Revenue and Profits:

Net Sales:

7 Million

(Quarterly Results - Sep 2025)

Net Profit:

0 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

9.3%

6 Months

49.08%

1 Year

314.81%

2 Years

318.61%

3 Years

3895.38%

4 Years

5.57%

5 Years

-43.54%

Precipio, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

36.34%

EBIT Growth (5y)

12.26%

EBIT to Interest (avg)

-8.41

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.04

Sales to Capital Employed (avg)

1.29

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

25.29%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

3.50

EV to EBIT

-22.38

EV to EBITDA

-46.54

EV to Capital Employed

3.84

EV to Sales

2.04

PEG Ratio

Dividend Yield

ROCE (Latest)

-17.18%

ROE (Latest)

-10.16%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bearish

Bollinger Bands

Mildly Bullish

Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bullish

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 3 Schemes (2.65%)

Foreign Institutions

Held by 1 Foreign Institutions (0.0%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 19.30% vs 16.33% in Jun 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is -200.00% vs 111.11% in Jun 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Jun'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "6.80",
          "val2": "5.70",
          "chgp": "19.30%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "0.40",
          "val2": "-0.40",
          "chgp": "200.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.10",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.10",
          "val2": "0.10",
          "chgp": "-200.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-9.00%",
          "val2": "-145.70%",
          "chgp": "13.67%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 21.71% vs 61.70% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 27.12% vs 51.64% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "18.50",
          "val2": "15.20",
          "chgp": "21.71%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.70",
          "val2": "-6.10",
          "chgp": "55.74%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "1.70",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-4.30",
          "val2": "-5.90",
          "chgp": "27.12%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-227.50%",
          "val2": "-501.40%",
          "chgp": "27.39%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ

Sep'25

Jun'25

Change(%)

Net Sales

6.80

5.70

19.30%

Operating Profit (PBDIT) excl Other Income

0.40

-0.40

200.00%

Interest

0.00

Exceptional Items

0.00

0.10

-100.00%

Consolidate Net Profit

-0.10

0.10

-200.00%

Operating Profit Margin (Excl OI)

-9.00%

-145.70%

13.67%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Sep 2025 is 19.30% vs 16.33% in Jun 2025

Consolidated Net Profit

QoQ Growth in quarter ended Sep 2025 is -200.00% vs 111.11% in Jun 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

18.50

15.20

21.71%

Operating Profit (PBDIT) excl Other Income

-2.70

-6.10

55.74%

Interest

0.10

0.00

Exceptional Items

0.00

1.70

-100.00%

Consolidate Net Profit

-4.30

-5.90

27.12%

Operating Profit Margin (Excl OI)

-227.50%

-501.40%

27.39%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 21.71% vs 61.70% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 27.12% vs 51.64% in Dec 2023

All Annual Results

Company CV

About Precipio, Inc.

Precipio, Inc.

Pharmaceuticals & Biotechnology

Precipio, Inc. is a cancer diagnostics company providing diagnostic products and services to the oncology market. The Company’s platform is designed to provide physicians and their patients access to necessary technology in order to provide diagnoses. The Company is focused on developing various technologies including IV-Cell, HemeScreen and ICE-COLD-PCR (ICP). The IV-Cell is a proprietary culture media that addresses the problem of selective culturing-by creating a universal media that enables simultaneous culturing of hematopoietic cell lineages. ICP is a specimen enrichment technology that increases the sensitivity of molecular based tests. The Company has developed a screening panel for genes in one rapid scanning panel, HemeScreen.

Company Coordinates

Company Details

12325 Emmet St , OMAHA NE : 68164-4243

Tel: 1 203 7877888

http://www.precipiodx.com/

Registrar Details